Form 4: Harmony Biosciences CFO Sandip Kapadia Sells Shares Under 10b5-1 Trading Plan

Harmony Biosciences CFO Sandip Kapadia executed sales of common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2025, Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan.
• A total of 6,987 shares were sold in two transactions.
• The first transaction involved the sale of 6,247 shares at a weighted average price of $32.4765, with prices ranging from $32.00 to $33.01.
• The second transaction involved the sale of 740 shares at a weighted average price of $33.1152, with prices ranging from $33.02 to $33.22.
• Following the reported transactions, the number of shares beneficially owned by Kapadia is 0.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard SEC filing detailing stock sales by an executive under a pre-arranged trading plan.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, Sandip Kapadia, Harmony Biosciences, HRMY, stock sale, Rule 10b5-1 plan, CFO, insider trading